Non-US-born physicians make up nearly half of the internal medicine workforce, with many serving underserved populations ...

Topline phase 3 INTerpath-001 trial results show adjuvant intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB-IV melanoma.

The risk for PV is greater in patients with type 2 diabetes who received DPP-4 inhibitors compared with those who received other medications.

Nemolizumab may be more effective across key pruritus and disease severity measures than dupilumab for patients with PN.

Patients with psoriasis and obesity may experience a reduced response to biologics, though further research is needed to confirm these findings.

More than 1 in 10 women (12 percent) positive for bacterial vaginosis (BV) are infected with at least one sexually transmitted infection (STI), according to a s ...

Patient reassurance that symptoms are normal can lead individuals to incorrectly infer that medical treatment is unnecessary.

FDA grants accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) plus nivolumab for adult patients with advanced PD-1-refractory melanoma.

Irritable bowel syndrome is associated with an elevated long-term risk for incident psoriasis across demographic groups.

Phase 3 ALKIVIA trial results show SC efgartigimod significantly improves clinical outcomes in adults with autoimmune myositis, including IMNM and dermatomyositis.

The rates of xenobiotic-induced liver injury have increased, with acetaminophen alone being the most frequently implicated xenobiotic.

NEWS2 values identify patients with suspected sepsis who require urgent antibiotic administration to reduce mortality.